Your browser doesn't support javascript.
loading
Peripheral Immunotype Correlates with Minimal Residual Disease Status and Is Modulated by Immunomodulatory Drugs in Multiple Myeloma.
Bhutani, Manisha; Foureau, David; Zhang, Qing; Robinson, Myra; Wynn, Adina S; Steuerwald, Nury M; Druhan, Lawrence J; Guo, Fei; Rigby, Katherine; Turner, Mitchell; Slaughter, Daniel; Friend, Reed; Atrash, Shebli; Symanowski, James T; Avalos, Belinda R; Copelan, Edward A; Voorhees, Peter M; Usmani, Saad Z.
Afiliação
  • Bhutani M; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, North Carolina.
  • Foureau D; Immune Monitoring Core Laboratory, Levine Cancer Institute/Atrium Health, Charlotte, North Carolina.
  • Zhang Q; Department of Cancer Biostatistics, Levine Cancer Institute/Atrium Health, Charlotte, North Carolina.
  • Robinson M; Department of Cancer Biostatistics, Levine Cancer Institute/Atrium Health, Charlotte, North Carolina.
  • Wynn AS; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, North Carolina.
  • Steuerwald NM; Molecular Biology Core Facility, Atrium Health, Charlotte, North Carolina.
  • Druhan LJ; Hematology Oncology Translational Research Laboratory, Levine Cancer Institute/Atrium Health, Charlotte, North Carolina.
  • Guo F; Immune Monitoring Core Laboratory, Levine Cancer Institute/Atrium Health, Charlotte, North Carolina.
  • Rigby K; Hematology Oncology Translational Research Laboratory, Levine Cancer Institute/Atrium Health, Charlotte, North Carolina.
  • Turner M; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, North Carolina.
  • Slaughter D; Department of Cancer Biostatistics, Levine Cancer Institute/Atrium Health, Charlotte, North Carolina.
  • Friend R; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, North Carolina.
  • Atrash S; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, North Carolina.
  • Symanowski JT; Department of Cancer Biostatistics, Levine Cancer Institute/Atrium Health, Charlotte, North Carolina.
  • Avalos BR; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, North Carolina.
  • Copelan EA; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, North Carolina.
  • Voorhees PM; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, North Carolina.
  • Usmani SZ; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, North Carolina. Electronic address: saad.usmani@atriumhealth.org.
Biol Blood Marrow Transplant ; 25(3): 459-465, 2019 03.
Article em En | MEDLINE | ID: mdl-30481597
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Imunofenotipagem / Neoplasia Residual / Imunomodulação / Mieloma Múltiplo Tipo de estudo: Prognostic_studies Limite: Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Imunofenotipagem / Neoplasia Residual / Imunomodulação / Mieloma Múltiplo Tipo de estudo: Prognostic_studies Limite: Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article